Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
3.220
+0.110 (3.54%)
At close: Nov 4, 2024, 4:00 PM
3.140
-0.080 (-2.48%)
After-hours: Nov 4, 2024, 4:01 PM EST
Vistagen Therapeutics Employees
As of March 31, 2024, Vistagen Therapeutics had 40 total employees, including 39 full-time and 1 part-time employees. The number of employees increased by 6 or 17.65% compared to the previous year.
Employees
40
Change (1Y)
6
Growth (1Y)
17.65%
Revenue / Employee
$24,275
Profits / Employee
-$829,800
Market Cap
87.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| So-Young International | 1,357 |
| Agenus | 389 |
| PetMed Express | 287 |
| I-Mab | 220 |
| WORK Medical Technology Group LTD | 216 |
| X4 Pharmaceuticals | 93 |
| Chimerix | 72 |
| BeyondSpring | 36 |
VTGN News
- 3 days ago - Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - Business Wire
- 20 days ago - Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
- 26 days ago - Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - Business Wire
- 6 weeks ago - Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 2 months ago - Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - Business Wire
- 3 months ago - Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 - Business Wire
- 4 months ago - Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine - Business Wire